Background/Aims: To study the 2-year course of children and adolescents with type 2 diabetes mellitus (T2DM) in general practice to present (1) the treatment modalities, (2) patient adherence, and (3) the occurrence of comorbidities. Methods: HBA1c, lipids, blood pressure, treatment modalities, occurrence of retinopathy and nephropathy were analyzed in 129 children and adolescents with T2DM (median age 13.4 years, 75% female) in specialized diabetes centers in Germany. Results: Seventy-eight (60%) children dropped out of care after a mean of 7.1 months. Drug treatment was not stopped in any of the 64 children initially treated with antidiabetic drugs. Sixteen (12%) children were treated solely by lifestyle intervention over the 2-year course. In the 51 children with complete follow-up, median HbA1c was 7.7% at diagnosis and 6.3% after 2 years. Less than 5% of all children were treated with antihypertensive or lipid-lowering drugs, while 65% suffered from hypertension and 44% from dyslipidemia. Over the course of the disease, retinopathy was not observed, while microalbuminuria occurred in 25%. Conclusions: In general practice, many children and adolescents with T2DM were lost of follow-up. Lifestyle intervention as sole treatment was not often useful for long-term metabolic control. Dyslipidemia and hypertension were seldom treated as recommended.

1.
American Diabetes Association: Type 2 diabetes in children and adolescents. Diabetes Care 2000;23:381–389.
2.
Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, Beckles GL, Saaddine J, Gregg EW, Williamson DF, Narayan KM: Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000;136:664–672.
3.
Reinehr T: Clinical presentation of type 2 diabetes mellitus in children and adolescents. Int J Obes (Lond) 2005;29(suppl 2):S105–S110.
4.
Arslanian SA: Type 2 diabetes in children: clinical aspects and risk factors. Horm Res 2002;57(suppl 1):19–28.
5.
Zdravkovic V, Daneman D, Hamilton J: Presentation and course of type 2 diabetes in youth in a large multi-ethnic city. Diabet Med 2004;21:1144–1148.
6.
Schober E, Holl RW, Grabert M, Thon A, Rami B, Kapellen T, Seewi O, Reinehr T: Diabetes mellitus type 2 in childhood and adolescence in Germany and parts of Austria. An estimate based on a prospective large quality-control database. Eur J Pediatr 2005;164:705–707.
7.
Ebbeling CA, Pawlak DB, Ludwig DS: Childhood obesity: public-health crisis, common sense cure. Lancet 2002;360:473–482.
8.
Grinstein G, Muzumdar R, Aponte L, Vuguin P, Saenger P, DiMartino-Nardi J: Presentation and 5-year follow-up of type 2 diabetes mellitus in African-American and Caribbean-Hispanic adolescents. Horm Res 2003;60:121–126.
9.
Consensus Guidelines of the International Society for Pediatric and Adolescent Diabetes 2000: http://www.d4pro.com/diabetesguidelines/
10.
German Guidelines for Diabetes Type 2 in Childhood and Adolescence: http://www.a-g-a.de/aga_content.html
12.
Holl RW, Grabert M: The quality circle: how to improve the outcome of paediatric diabetes care. Horm Res 2002;57(suppl 1):105–109.
13.
Cole TJ, Bellizzi MC, Flegal KM, Dietz WH: Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000;320:1–6.
14.
Cole TJ: The LMS method for constructing normalized growth standards. Eur J Clin Nutr 1990;44:45–60.
15.
Kromeyer-Hauschild K, Wabitsch M, Geller F, et al: Percentiles of body mass index in children and adolescents evaluated from different regional German studies. Monatsschr Kinderheilkd 2001;149:807–818.
16.
American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992;89:525–584.
17.
Rosner B, Prineas RJ, Loggie JM, Daniels K: Blood pressure normograms for children and adolescents by height, sex, and age, in the United States. J Pediatr 2003;123:871–886.
18.
American Diabetes Association: Nephropathy in diabetes. Diabetes Care 2004;27:S79–S83.
19.
Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ: Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002;25:89–94.
20.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–412.
21.
Olivarius N, Andreasen H, Siersma V, Richelsen B, Beck-Nielsen H: Changes in patient weight and the impact of antidiabetic therapy during the first 5 years after diagnosis of diabetes mellitus. Diabetologia 2006; DOI: 10.1007/s00125–006–0328-y.
22.
Csernus K, Lanyi E, Erhardt E, Molnar D: Effect of childhood obesity and obesity-related cardiovascular risk factors on glomerular and tubular protein excretion. Eur J Pediatr 2005;164:44–49.
23.
Gale EA: Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 2005;48:2195–2199.
24.
Reinehr T, Schober E, Wiegand S, Thon A, Holl R: β-Cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? Arch Dis Child 2006;91:473–477.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.